<DOC>
	<DOCNO>NCT01750905</DOCNO>
	<brief_summary>The promising chimeric natriuretic peptide design study group CD-NP anti-fibrotic cardioprotective property vivo , vitro normal volunteer human heart failure patient . Since leave ventricular assist device ( LVAD ) reverse remodel heart whereas improve hemodynamics , CD-NP may novel anti-fibrotic anti-remodeling drug co-therapy LVAD support .</brief_summary>
	<brief_title>Safety Study Chimeric Natriuretic Peptide ( CD-NP ) Stable LVAD Patients</brief_title>
	<detailed_description>This study double blind , placebo-controlled phase I trial safety neurohumoral activity CD-NP , treatment heart failure LVAD support . Subjects 3 month LVAD implantation screen outpatient clinic visit appointment list interested qualified subject either confront visit send letter mail consent offer participation trial . Once consent obtain , baseline value establish day 1 subject give subcutaneous injection placebo CD-NP stay overnight two different visit Clinical Research Unit ( CRU ) . Participant 's receive placebo CD-NP study , one per visit . A final follow-up visit clinical assessment conduct phone end study . Potential subject present Mayo Clinic , Rochester , Minnesota follow clinical visit LVAD implantation identify study coordinator . A $ 300 remuneration per subject involve compensate inconvenience subject . A $ 500 reimbursement gas mileage provide travel .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Inclusion Criteria Male nonpregnant/postmenopausal female , age 1890 , endstage Heart Failure ( HF ) LVAD support stable heal stage least 3 month LVAD implant ( Destination therapy ) ( postmenopausal state define absence menses ≥ 1 year serum folliclestimulating hormone ≥ 20 IU/L ; sterilization female define bilateral tubal occlusion ≥ 6 month , bilateral oophorectomy , complete hysterectomy ) Be willing provide inform consent . Exclusion Criteria Known allergy adverse reaction exogenous natriuretic peptide ( CDNP component , nesiritide , natriuretic peptide , related compound ) . Women pregnant , breastfeed . Having receive nesiritide within 7 day prior prior entry study . Having receive investigational drug device within 30 day prior entry study . Clinically unstable patient ( e.g . mean blood pressure &lt; 70 mmHg , ongoing requirement vasopressor , mechanical ventilation ) . Recent hospitalization decompensated HF recent defibrillation cardiac resuscitation within 30 day prior randomization . Patients guard prognosis unlikely derive meaningful benefit CDNP . Use sulfonamide , nonsteroidal antiinflammatory drug , probenecid , drug know alter renal function within one week first dose CDNP placebo . Presence cardiac lesion comorbidities may contraindicate use natriuretic peptide , clinically significant cardiac valvular stenosis , hypertrophic cardiomyopathy , restrictive cardiomyopathy , constrictive pericarditis , primary pulmonary hypertension , uncorrected congenital heart disease contraindicates use vasodilator . Symptomatic carotid artery disease , know critical carotid stenosis , stroke within past 3 month Clinically significant renal artery stenosis Baseline hemoglobin &lt; 9.0 g/dl . Serum sodium &lt; 130 mEq/L , potassium &lt; 3.6 milliequivalent per Liter ( mEq/L ) , magnesium &lt; 1.5 mEq/L . Elevated aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) least 5 time upper limit normal bilirubin least 5 time upper limit normal Creatinine clearance ( CrCl ) &lt; 30 ml.min1.1.73m2 , calculate CockcroftGault formula ( 35 ) adjust body surface area within 3 month screen , requirement dialysis . History alcohol drug abuse within past 6 month . Inability communicate effectively study personnel . BMI &gt; 40</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>